Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P18577
UPID:
RHCE_HUMAN
Alternative names:
Rh polypeptide 1; Rh30A; RhIXB; Rhesus C/E antigens
Alternative UPACC:
P18577; A7DW68; B7UDF3; B7UDF4; B7UDF5; B7UDF6; B7UDF7; B7UDF8; B7UDF9; B7UDG0; B7UDG1; B7UDG2; B7UDG3; Q02163; Q02164; Q02165; Q16160; Q2MJW0; Q2VC86; Q3LTM6; Q6AZX5; Q6J2U3; Q7RU06; Q8IZT2; Q8IZT3; Q8IZT4; Q8IZT5; Q9UD13; Q9UD14; Q9UD15; Q9UD16; Q9UD73; Q9UD74; Q9UEC2; Q9UEC3; Q9UPN0
Background:
The Blood group Rh(CE) polypeptide, known alternatively as Rh polypeptide 1, Rh30A, RhIXB, and Rhesus C/E antigens, plays a crucial role in the stability and shape of the erythrocyte membrane. It is a component of the ankyrin-1 complex, essential for mediating the primary membrane attachment site for ANK1 in association with RHAG. This protein is also implicated in the transport of ammonium and carbon dioxide.
Therapeutic significance:
The Rh(CE) polypeptide is linked to Rh-null, amorph type, a condition marked by hemolytic anemia and adverse reactions to transfusion or pregnancy due to the absence of Rh antigens. Understanding the role of Blood group Rh(CE) polypeptide could open doors to potential therapeutic strategies for managing this condition.